As a consequence of excess abdominal adiposity and genetic predisposition, type 2 diabetes is a progressive disease, often diagnosed after metabolic dysfunction has taken hold of multiple organ systems. Insulin deficiency, insulin resistance and impaired glucose homeostasis resulting from beta-cell dysfunction characterize the disease. Current treatment goals are often unmet due to insufficient treatment modalities. Even when combined, these treatment modalities are frequently limited by safety, tolerability, weight gain, edema and gastrointestinal intolerance. Recently, new therapeutic classes have become available for treatment. This review will examine the new therapeutic classes of incretin mimetics and enhancers in the treatment of type 2 diabetes.
Abraham, E.J., Leech, C.A., Lin, J.C., Zulewski, H., Habener, J.F. et al. (2002) Insulinotropic hormone glucagons-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology143: 3152.
2.
ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med358: 2560.
3.
Amori, R.E., Lau, J. and Pittas, A.G. ( 2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA298: 194.
4.
Aschner, P., Kipnes, M.S., Lunceford, J.K., Sanchez, M., Mickel, C., Williams-Herman, D.E. et al. (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes . Diabetes Care29: 2632-2637.
5.
Blase, E., Deng, W., Walsh, B., Fineman, M. and Rhodes, C. ( 2008) Intranasal administration of exenatide in patients with type 2 diabetes: pharmokinetics, pharmodynamics, safety, and tolerability . Program and abstracts of the American Diabetes Association (ADA) 68th Scientific Sessions, 6-10 June 2008, San Francisco, p. 484.
6.
Bjerre, K.L., Moller Knudsen, S., Wilken, M. et al. (2005) Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its efficacy. Diabetes52(Suppl. 1): 321-322.
7.
Blonde, L., Klein, E.J., Han, J., Zhang, B., Mac, S.M., Poon, T.H. et al. (2006) Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab8: 436-447.
8.
Blonde, L., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H. et al. (2008) Liraglutide: superior glycemic control versus exenatide when added to metformin and/or sulphonylurea in type 2 diabetes (LEAD-6). Poster presented at the Canadian Diabetes Association Congress, 15-18 October, Montreal, Canada.
Charbonnel, B., Karasik, A., Liu, J., Wu, M. and Meininger, G. ( 2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformon therapy in patients with type 2 diabetes inadequetly controlled on metformin alons. Diabetes Care29: 2638-2643.
11.
Chia, C.W. and Egan, J.M. ( 2008) Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrin Metab93: 3703-3716.
12.
Croxtall, J.D. and Keam, S.J. ( 2008) Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs68(16): 2387-2409.
13.
Davis, S.N., Johns, D., Maggs, D., Xu, H., Northrup, J.H., Brodows, R.G. et al. (2007) Exploring the subsitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care30: 2767.
14.
DeFronzo, R.A., Ratner, R.E., Han, J., Kim, D.D., Fineman, M.S. and Baron, A.D. ( 2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care28: 1092.
15.
De Leon, D.D., Crutchlow, M.F., Nina Ham, J.-Y. and Stoffers, D.A. ( 2006) Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol38: 845-859.
16.
Drucker, D.J., Buse, J.B. and Taylor, K. ( 2008) Exenatide once weekly results in significantly greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. Program and abstracts of the American Diabetes Association (ADA) 68th Scientific Session, 6-10 June, California, Abstract 107-OR.
17.
Goldstein, B.J., Feinglos, M.N., Lunceford, J.K., Johnson, J. and Williams-Herman, D.E. ( 2007) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care30: 1979-1987.
18.
Handelsman, Y. ( 2008) Treating diabetes with incretin hormones - clinical experience . PER5: 897-903.
19.
Jellinger, P.S., Davidson, J.A., Blonde, L., Einhorn, D., Grunberger, G., Handelsman, Y. et al. (2007) Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract13: 260-268.
20.
Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J.R., Colarusso, A. et al. (2008) Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab93: 2479-2485.
21.
Litwin, S.E. ( 2006) The growing problem of obesity and the heart: the plot ‘thickens’. J Am Coll Cardiol47: 617-619.
22.
Meier, J.J. ( 2008) Beta cell mass in diabetes: a realistic therapeutic target ? Diabetologia51: 703-713.
23.
Miller, W.M., Nori Janosz, K.E., Yanez, J. and McCullough, P.A. ( 2005) Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease. Expert Rev Cardiovasc Ther3: 743-759.
24.
McIntyre, N., Holdsworth, C.D. and Turner, D.S. ( 1964) New interpretation of oral glucose tolerance. Lancet4: 20-21.
25.
Nathan, D.M. ( 2007) Finding new treatments for diabetes - how many, how fast.. how good?N Engl J Med356: 437-440.
26.
Nauck, M.A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A. et al. (2007) A comparision of twice-daily exenatide and biphasic insulin asprt in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia50: 259.
27.
Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H. et al. (2008) Efficacy and safety comparison of Liraglutide, Glimepiride, and Placebo, all in combination with metformin in type 2 diabetes . Diabetes Care32: 84-90.
28.
Nielsen, L.L., Young, A.A. and Parks, D.G. ( 2004) Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept117: 77-88.
29.
Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D. et al. (2004) Effects of glucagons-like-peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation109: 962-965.
30.
Nystrom, T., Gutniak, M.K., Zhang, Q., Zhang, F., Holst, J.J., Ahrén, B. et al. (2004) Effects of glucagons-like-peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab287: E1209-1215.
31.
Pratley, R.E. ( 2008) Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape Journal10: 171.
32.
Ratner, R.E., Maggs, D., Nielsen, L.L., Stonehouse, A.H., Poon, T., Zhang, B. et al. (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab8: 419.
33.
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D. and Khatami, H. ( 2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia49: 2564-2571.
34.
Rodbard, H.W., the AACE Diabetes Mellitus Clinical Practice Guidelines Task Force (2007) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract13 (Suppl. 1): 3-68.
35.
Rosenstock, J., Brazg, R., Andryuk, P.J., Lu, K. and Stein, P. ( 2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther28: 1556-1568.
36.
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F.L., Powe, N.R. et al. (2004) Meta-analysis:glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med141: 421.
37.
Tominaga, M., Eguchi, H., Manaka, H., Igarashi, K., Kato, T. and Sekikawa, A. ( 1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care22: 920-924.
38.
Toft-Nielson, M.B., Darnholt, M.B., Madsbad, S., Hilsted, L.M., Hughes, T.E., Michelsen, B.K. et al. (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab86: 3717-3723.
39.
Turner, R.C., Cull, C.A., Frighi, V., Holman, R.R.; UK Prospective Diabetes Study Group (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UJPDS 49). JAMA281: 2005-2012.
40.
Vilsboll, T., Zdravkovic, M. and Le-Thi, T. ( 2006) Beneficial effects of the GLP-1 analogue liraglutide on blood pressure and cardiovascular risk markers in subjects with type 2 diabetes . Diabetic Med23(Suppl. 4): 696.
41.
Vilsboll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.P. et al. (2007) Liraglutide, a long-acting human glucagon-like peptide -1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care30: 1608-1610.
42.
Williams-Herman, D. ( 2008) Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord8: 14.
43.
Williamson, D.F., Thompson, T.J., Thun, M., Flanders, D., Pamuk, E., Byers, T. et al. (2000) Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care23: 1499-1505.
